An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Catalent, Inc. to Present at March Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) has announced participation in two major investor conferences in March 2023. The first event is the Barclays Global Healthcare Conference on March 14 at 10:45 a.m. ET, followed by the KeyBanc Life Sciences & MedTech Investor Forum on March 21 at 12:00 p.m. ET. Interested investors can access a live webcast of both presentations through the Catalent investor relations page. Catalent, headquartered in Somerset, New Jersey, generated nearly $5 billion in revenue for the 2022 fiscal year and is a leader in the development and supply of pharmaceutical and biotech treatments.
Positive
None.
Negative
None.
SOMERSET, N.J.--(BUSINESS WIRE)--
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at two upcoming investor conferences.
On March 14, 2023 at 10:45 a.m. ET, the Company will present at the Barclays Global Healthcare Conference.
On March 21, 2023, at 12:00 p.m. ET, the Company will present at the KeyBanc Life Sciences & MedTech Investor Forum.
A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.
About Catalent Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.
